Abstract |
The present study aimed to evaluate the effect of liver metastases on the efficacy from the combination of PD-1/ PD-L1 inhibitor with chemotherapy as first-line treatment in lung cancer using the meta-analysis. A total of 8 randomized controlled trials (RCTs) were included. In patients without liver metastases, PD-1/ PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 40% and risk of death by 29% (HR = 0.60; 95%CI,0.55- 0.65 and HR = 0.71;95%CI,0.58-0.90 respectively). In patients with liver metastases, PD-1/ PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 31% and risk of death by 21% (HR = 0.69;95%CI,0.58-0.81; and HR = 0.79; 95%CI,0.62-0.80, respectively). The pooled ratios of PFS-HRs and OS- HRs reported in lung cancer patients with liver metastases versus those without liver metastases were 1.11 (95%CI, 0.92-1.34) and 1.03 (95%CI, 0.80-1.35), respectively, suggesting that lung cancer patients with and without liver metastases could obtain comparable efficacy.
|
Authors | Bao-Dong Qin, Xiao-Dong Jiao, Jun Liu, Ke Liu, Xi He, Ying Wu, Yan Ling, Xiao-Peng Duan, Wen-Xing Qin, Zhan Wang, Yuan-Sheng Zang |
Journal | Critical reviews in oncology/hematology
(Crit Rev Oncol Hematol)
Vol. 147
Pg. 102893
(Mar 2020)
ISSN: 1879-0461 [Electronic] Netherlands |
PMID | 32065969
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- B7-H1 Antigen
- Programmed Cell Death 1 Receptor
|
Topics |
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- B7-H1 Antigen
- Carcinoma, Non-Small-Cell Lung
(pathology, therapy)
- Humans
- Immunotherapy
- Liver Neoplasms
(pathology, therapy)
- Lung Neoplasms
(pathology, therapy)
- Programmed Cell Death 1 Receptor
(analysis, immunology)
|